One-Pager: EpiScreen® Technology To Advance Immunogenicity Assessments
Optimize Your Immunogenicity Assessment with Next-Generation EpiScreen® Technology
To avoid issues later in the drug development process, you need to start smart.
That means you need more data-rich assays at the start of your project. We have recently introduced our next-generation EpiScreen® technology to elevate the immunogenicity evaluation of protein therapeutics, offering high sensitivity and a multi-dimensional, data-rich platform that streamlines candidate selection.
Why choose EpiScreen® Technology?
Accurate assessment of immunogenicity can make or break the success of protein therapeutics. Traditional assays often lack the sensitivity and specificity required for comprehensive evaluation. The Next-Generation EpiScreen® PBMC Time Course Assay is Abzena’s innovative answer to these challenges, utilizing flow cytometry technology for precise, multi-dimensional immunogenicity assessments.
